ArticleCancer immunology, immunotherapy : CII2020

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies.

Csaba Kerepesi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.